ABPI response to NI Protocol update

The UK government has published a Written Ministerial Statement giving an update on the Northern Ireland Protocol. 

Removing the cliff-edge at the end of the year is a pragmatic step and a welcome response to the concerns that our members have raised about supplying medicines under the Northern Ireland Protocol. Richard Torbett

In it, they say the UK would continue to operate the Protocol “on the current basis,” meaning that existing arrangements continue in force, including extending specific arrangements, easements, and grace periods.

In response, Richard Torbett, Chief Executive, the Association of the British Pharmaceutical Industry, said:

“Removing the cliff-edge at the end of the year is a pragmatic step and a welcome response to the concerns that our members have raised about supplying medicines under the Northern Ireland Protocol. We still need to see the detail behind this statement so that our companies have the assurances they need, but this is a positive move.

“Ultimately, both sides know we need a long-term answer to supplying medicines under the Protocol. The UK and the EU must use this extra time to work constructively towards an agreed solution.”

TAGS
  • Northern Ireland

The ABPI exists to make the UK the best place in the world to research, develop and use new medicines. We represent companies of all sizes who invest in discovering the medicines of the future. 

Our members supply cutting edge treatments that improve and save the lives of millions of people. We work in partnership with Government and the NHS so patients can get new treatments faster and the NHS can plan how much it spends on medicines. Every day, we partner with organisations in the life sciences community and beyond to transform lives across the UK.